Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 6/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | LAP3 | P28838 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28305103 | 1.00 | S1PR2 (0.52) | S1PR2S1PR1S1PR3S1PR4ALDH1A1 | |
| SCHEMBL1561204 | 1.00 | S1PR2 (0.52) | S1PR2S1PR1S1PR3S1PR4ALDH1A1 | |
| SCHEMBL6874674 | 0.91 | CA2 (0.43) | S1PR2S1PR1S1PR3S1PR4ALDH1A1 | |
| SCHEMBL25754164 | 0.91 | CA2 (0.43) | S1PR2S1PR1S1PR3S1PR4ALDH1A1 | |
| SCHEMBL28329552 | 0.88 | FAAH (0.50) | S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL6802942 | 0.83 | S1PR2 (0.52) | S1PR2S1PR1S1PR3S1PR4ALDH1A1 | |
| SCHEMBL5419098 | 0.83 | S1PR2 (0.63) | S1PR2S1PR1S1PR3S1PR4ALDH1A1 | |
| SCHEMBL4390623 | 0.83 | S1PR2 (0.63) | S1PR2S1PR1S1PR3S1PR4ALDH1A1 | |
| SCHEMBL22660994 | 0.83 | S1PR2 (0.63) | S1PR2S1PR1S1PR3S1PR4ALDH1A1 | |
| SCHEMBL10804885 | 0.83 | S1PR2 (0.63) | S1PR2S1PR1S1PR3S1PR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264419-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | APP, BACE1, APBA1 | S1PR2 3913/4885S1PR1 3789/4885S1PR3 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.